XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience technology accelerator, recently announced that its distribution, storage and logistics partner, Max Pharma GmbH, began selling and delivering its 25-minute COVID-19 RT-PCR test system (“Covid-ID Lab”) in Germany on May 25. The company is likely to benefit from the country’s regulatory requirements and the government’s initiative that qualifies every resident to at least one free COVID-19 test per week. “Covid-ID Lab combines the accuracy of a PCR test, the gold standard for diagnosis, with the speed of an antigen test, thereby filling the existing market gap between centralized, automated PCR systems and disposable antigen tests,” reads a recent article. “It achieves this despite requiring less laboratory equipment and expertise. Notably, the high accuracy may well make XPhyto’s rapid test kit the go-to product on the market, increasing its demand.”
To view the full article, visit https://ibn.fm/e6uzI
About XPhyto Therapeutics Corp.
XPhyto Therapeutics is a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, including precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications, including psychedelic compounds and cannabinoids. The company has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets. For more information, visit the company’s website at www.Xphyto.com.
NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.